Market Overview

REVLIMID-Treated Patients with Deletion-5q MDS Who Achieve Transfusion-Independence of At Least 26 Weeks and AML-Free Survival Associated with Cytogenetic Response


Celgene International Sàrl, a wholly-owned subsidiary of Celgene
Corporation (NASDAQ: CELG) today announced that results from a
retrospective analysis of patients with International Prognostic Scoring
System (IPSS) Low- or Intermediate (Int)-1-risk myelodysplastic
syndromes (MDS) with del(5q) treated with REVLIMID® (lenalidomide) were
presented at the American Society of Hematology annual meeting in New
Orleans, La.

In the analysis, 286 patients from the MDS-003 and MDS-004 studies
received lenalidomide from the study start. Of the total, 181 were
evaluable for both cytogenic response (CyR) and red-blood cell
transfusion independence (RBC-TI) of at least 26 weeks, (88 patients
from MDS-003 and 93 patients from MDS-004).

See full press release

Posted-In: News Guidance Contracts Management Global


Related Articles (CELG)

View Comments and Join the Discussion!

Partner Center